📱 Now on iPhone — live scores, valuations & alerts on the go
ULTRALIFE CORP (ULBI)
Technology
Inconclusive
weak
$15.62
Updated: 2026-10-31
Next earnings: Nov 16 (est.)
As of October 31, 2026, TradeApes rates ULTRALIFE CORP (ULBI) 42 out of 100 (Weak); valuation verdict: Inconclusive.
42
TradeApes Score
Financial Strength
56
Mixed
Operating Trend
31
Weak
Relative Value
23
Overvalued
Capital Allocation
49
Mixed
Risk Management
61
Healthy
Methods disagree
Our methods don't agree
Sector Rank
#1148
of 1300
Cash-flow model implies $1.77,
Peer multiples implies $4.89 —
a 2.8× gap. We won't average that into one fair value.
Our methods couldn't reach a reliable fair value for ULBI yet — our cash-flow model and peer multiples are too far apart to publish one number.
Key Findings
What's working
- + Generates cash — not dependent on raising money
- + Stock-based compensation is 0% of revenue — low
- + Accruals are -8% of assets — earnings backed by cash
What to watch
- − Margins compressing 11.0 points — costs outpacing sales
- − Earnings yield -5.8% (P/E about —) — no earnings to value
- − Operating margin contracted 11.0 points over about three years — eroding profitability
AI-written analysis
The full ULTRALIFE CORP (ULBI) analysis
Industry Related Stocks
TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor.
The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.
Sign up for our Weekly Sector Leaders Newsletter
11 sector-leading stocks delivered to your inbox every Sunday. Free.
No spam. Unsubscribe anytime.